Clinical Trial Update: Sabatolimab as a Treatment for Patients With Acute Myeloid Leukemia and Presence of Measurable Residual Disease After Allogeneic Stem Cell Transplantation. [Phase 1, Phase 2]

View source ↗

Summary

A clinical trial update reports that Sabatolimab was studied for acute myeloid leukemia with measurable residual disease after allogeneic stem cell transplantat…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Acute Myeloid Leukemia

Drugs mentioned

• Sabatolimab (sabatolimab)

Snippet

Sponsor: Novartis Pharmaceuticals | Conditions: Acute Myeloid Leukemia | Phase 1, Phase 2 | Status: TERMINATED | Results posted: 2025-06-03